Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBT Margin: 2024-2025

Historic EBT Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -236.98%.

  • Monte Rosa Therapeutics' EBT Margin rose 2113.00% to -236.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.09%, marking a year-over-year change of. This contributed to the annual value of -92.74% for FY2024, which is N/A change from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EBT Margin stood at -236.98% for Q3 2025, which was down 395.37% from -47.84% recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EBT Margin registered a high of 56.17% during Q1 2025, and its lowest value of -2,996.71% during Q1 2024.
  • Moreover, its 2-year median value for EBT Margin was -236.98% (2025), whereas its average is -585.42%.
  • Data for Monte Rosa Therapeutics' EBT Margin shows a peak YoY spiked of 305,288bps (in 2025) over the last 5 years.
  • Monte Rosa Therapeutics' EBT Margin (Quarterly) stood at 25.72% in 2024, then spiked by 2,113bps to -236.98% in 2025.
  • Its EBT Margin stands at -236.98% for Q3 2025, versus -47.84% for Q2 2025 and 56.17% for Q1 2025.